Prostate Screening Study Using MRI in BRCA Carriers

Men with a BRCA1 or BRCA2 mutation are at increased risk for early onset, aggressive prostate cancer compared to men in the general population. Standard of care screening for men with a BRCA mutation includes PSA testing and digital rectal examination (DRE), the same as with men in the general population. This study is being done to assess whether there is value in using MRI as a screening tool to detect prostate cancer at an earlier stage than may otherwise be detected using standard of care screening (PSA, DRE). It is unclear whether MRI has utility as a screening tool in this specific population at high risk for aggressive disease.

Sex

Male

Minimum age

50 Years

Inclusion Criteria:

* Enrolled in the Male Hereditary Cancer Research Program at Sunnybrook Health Sciences Center.
* Have positive genetic testing for a pathogenic BRCA1 or BRCA2 mutation.
* Clinically eligible for and willing to undergo ultrasound biopsy within 4 weeks after the MRI.
* Be 50 years of age or older.

Exclusion Criteria:

* Claustrophobia
* Contraindication to MRI
* Contraindication to receiving low molecular weight MRI contrast agent
* Previously diagnosed with prostate cancer